Nabla Bio Processes 30 Billion Tokens a Month Across 130 Health Systems. The Engineers Who Can Build That Infrastructure Are Being Hunted by Mistral, Meta, and Google at Twice the Salary.

A Billion-Dollar Validation for AI-Driven Biologics

Nabla Bio raised $70 million in a Series C round led by HV Capital, with Highland Europe, DST Global, Cathay Innovation, and Tony Fadell's Build Collective participating, according to PRNewswire. Weeks later, Takeda signed a second multi-year collaboration that could exceed $1 billion in success-based payments, pairing Nabla's generative AI protein-design platform with Takeda's early-stage therapeutic pipeline.

The two announcements mark a step-change. Takeda isn't licensing a tool; it's embedding Nabla's de novo protein-design engine directly into its discovery workflow. That move signals AI-driven biologics have crossed from pilot projects into core R&D strategy at a top-15 global pharmaceutical company.

Nabla's platform uses generative AI to design protein therapeutics from scratch, then validates them through human-relevant wet-lab experiments. The Takeda deal deploys that capability broadly across early-stage programs, building on a prior collaboration that both sides said produced step-change improvements in hit rates and molecular properties. It fits Takeda's narrower R&D focus, which has seen the company walk away from cell therapy to concentrate on three core modalities.

PRNewswire reported the round brings Nabla's total funding to $120 million and will fund the buildout of its technical and go-to-market teams. Several open roles are already listed on Zero G Talent's board, including a Senior Security Engineer and Backend Engineer based in Paris. The company's lean structure (60% engineering) reflects a team that ships product rather than publishing papers.

For the talent market, the signal is concrete: AI-native drug design has a well-funded, billion-dollar-partnered company hiring in Paris, and the roles it's creating don't look like anything a traditional pharma job board would recognize.

Why Paris — and Why Now

Nabla operates from two offices: Paris and New York. The Paris hub, in the 3rd arrondissement near Arts & Métiers, has become the company's primary engineering base. Most US biotech recruiters aren't looking there.

The postings aren't the usual computational biology listings. Nabla is hiring Staff and Senior Machine Learning Engineers in Paris to build agentic AI systems that initiate EHR commands, guide coding, and execute actions inside clinical workflows. Open positions require fluency in transformer-based models, LLM fine-tuning, and production-scale ML infrastructure. Several roles require full professional fluency in both French and English, a detail that signals how deeply embedded the team is in the local talent market.

The hiring extends beyond pure ML. Nabla's subsidiary, focused on AI-driven antibody design, recruits computational biologists out of Cambridge, MA. The split reveals how the company allocates work: protein-design and therapeutic R&D run from the US, while the agentic platform, clinical AI, and core ML engineering scale out of Paris.

The city has quietly built a cluster that competes for the same profiles as Mistral AI, Meta FAIR, and Amazon Science. Nabla's clinical AI focus (ambient listening, dictation, coding, command execution) demands a hybrid skill set that pure-play LLM labs don't always need. Engineers there work on context engineering for agents, data strategy for training and evaluation, and ML infrastructure decisions tied to healthcare-specific constraints like privacy, accuracy, and EHR integration.

Compensation reflects the competition. Nabla offers stock ownership, 100% healthcare coverage, meal vouchers, 50% public transit reimbursement, and an unlimited book budget, a bundle designed to match what Paris-based AI labs offer while accounting for French employment norms. The careers page emphasizes output over clock-in time, with a remote policy of one to two days per week plus the option to work remotely for one or two weeks per year.

For US-based talent watching the biotech job market, Paris has been off the radar. That's the point. The roles are open, the capital is deployed, and the hiring bar is set by a team that includes former Meta AI Research engineers. If you have ML-for-healthcare experience and can work in French and English, this is one of the more concentrated opportunities in European biotech that most US candidates have never considered.

These Aren't Your Typical Biotech Job Descriptions

Nabla's open positions read like nothing a Big Pharma HR department has ever written. The company wants protein engineers who can run yeast display selections and collaborate with dry-lab scientists to test machine-learning-generated antibody designs. That hybrid (wet-lab expertise paired with fluency in ML pipelines) defines the new roles emerging at the intersection of agentic AI and therapeutic antibody design.

The Protein Engineer listing for Cambridge, MA requires a Ph.D. in molecular biology or biochemistry plus hands-on experience with MACS/FACS, NGS, and SPR. Standard enough for a biotech shop. But the role also demands that candidates "work together with our dry-lab and other wet-lab scientists to establish a rapid and seamless production and pipeline for characterizing machine learning generated antibody designs." That sentence doesn't appear in a conventional pharma R&D posting. It describes a feedback loop between experimental biology and AI model iteration, a workflow that didn't exist at scale five years ago.

The Protein Engineering Scientist role in Boston makes the hybrid requirement even more explicit. Candidates need a BS or MS in the life sciences with one to two years of research experience, but the job centers on "developing and performing high-throughput and multiplex assays for evaluating antibody function" specifically to feed ML-generated designs through rapid validation. Nabla is upfront about the pace: the environment is "fast-moving" and the team will "invest heavily in training you."

Then there are positions that don't map onto any traditional biotech category. Zero G Talent's board shows Nabla recently added a Backend Engineer and a Senior Security Engineer at its Paris office, alongside a Lead Counsel, Corporate & Equity role, all in the past seven days. These are infrastructure hires, the kind you'd expect at a Series C SaaS company, not a biologics startup. They reflect the reality that Nabla's platform generates and processes enormous volumes of experimental data, which means it needs production-grade software engineering and data security just as much as it needs pipettes.

The conventional pharma R&D ladder assumes a linear progression through experimental biology. Nabla's hiring pattern breaks that mold. The company needs people who can operate at the boundary between computational design and physical validation, building teams where a backend engineer and a protein engineer sit in the same sprint cycle. That structure makes these roles hard to fill: the talent pool combining deep molecular biology training with comfort in an ML-driven workflow is still small, and it's being hunted simultaneously by foundation-model labs and hyperscalers paying top of market for generalist ML engineers.

130 Health Systems and Counting

Nabla's AI assistant is now embedded in more than 130 US healthcare organizations — academic medical centers, safety-net hospitals, community health centers, and physician groups, according to PRNewswire. These aren't pilot programs but live deployments processing real patient encounters. Named customers include CVS Health, Children's Hospital Los Angeles, Denver Health, Carle Health, and University of Iowa Health Care.

That scale matters for hiring because it shifts the company's needs from proof-of-concept engineering to the unglamorous work of running and improving a product clinicians depend on every day. PRNewswire reported Nabla supports more than 85,000 clinicians, processes over 30 billion tokens per month, and multiplied revenue five-fold in the six months leading up to the Series C. The company's current open roles — a Senior Security Engineer in Paris, an Enterprise Customer Success Director in the US, a Backend Engineer in Paris — only exist when a company needs to harden infrastructure, support enterprise clients, and keep pace with a growing user base.

The deployment data also explains why Nabla is expanding beyond documentation into what it calls an "agentic model" of clinical AI. When 130 health systems and 85,000 clinicians generate that volume of real-world usage, the feedback loops are tight. Peer-reviewed studies from University of Iowa Health Care and real-world data from Denver Health confirmed significant reductions in clinician burnout and a 15-point increase in patient satisfaction. Those outcomes give health-system procurement teams the evidence to expand contracts, which gives Nabla the revenue confidence to build a Proactive Coding Agent, a Context-Aware Agent that initiates EHR commands, and a Custom Care Setting Agent for nurses and inpatient teams. Each product line requires engineers who understand both machine learning and the messy reality of clinical workflows — a combination that is scarce and expensive, and that Nabla is now hiring aggressively to find.

The Talent War Nabla Can't Outspend

Nabla's funding and Takeda partnership have put it in a strong position to scale. But the hiring it needs (ML engineers, computational biologists, AI-agent designers) puts it in direct competition with employers that can outspend it by an order of magnitude.

Sources: University of Pittsburgh Department of Computational and Systems Biology (Glassdoor, Indeed, BLS, January 2025); PharmaPayWatch analysis of 218 postings.

Those upper bounds are outliers in biotech; they're floors at some AI-native companies. The competition isn't just about salary. A computational biologist joining Nabla is joining a company with a real product deployed across more than 130 US healthcare organizations and a partnership that validates the science. But a candidate weighing that against Google DeepMind or OpenAI is weighing a known brand, a larger research budget, and equity in a company valued in the hundreds of billions.

Paris adds another layer. France's tech salaries have risen sharply but still trail US benchmarks. A senior scientist role in Paris won't match Boston or San Francisco, where biotech salaries carry a 30–40% location premium. Nabla can offset this with mission appeal and quality of life, but it can't ignore the arithmetic.

Large tech companies with life-science units (Google's Verily, Microsoft, Amazon Web Services) "may pay more, with roles like 'Data Scientist' offering compensation akin to software standards," according to a LinkedIn analysis of bioinformatics career ladders. That is the pool Nabla is fishing in. Every backend engineer or ML researcher the company tries to hire in Paris is a candidate that Anthropic, Mistral, or Meta's AI research division is also pursuing.

Zero G Talent's board currently lists two open Nabla roles added in the past week: a Senior Security Engineer and a Backend Engineer, both in Paris. The aperture is narrow relative to the scale of its funding, suggesting either a deliberate focus on senior hires or a recruiting pipeline moving slowly against stiff competition.

The candidates who end up at Nabla will likely care more about the specific problem (designing protein therapeutics with AI agents) than about maximizing total comp. That's a real filter and a real advantage. But it's a smaller pool than the one Big Tech draws from, and Nabla's hiring timeline will reflect that.

Working in frontier tech? Zero G Talent tracks the openings: browse frontier tech jobs, openings at Nabla Bio, and the people building the field.